Contents

Chapter 1: Introduction ........................................... 1
  Information, Tips, and Tools for Implementation .......... 1
  Medicare Quality Initiatives ..................................... 2
  Implementing the Process ......................................... 3

Chapter 2: An Overview of PQRS and Other Quality Initiatives .......................................................... 7
  Institute of Medicine ................................................. 7
  Identifying and Prioritizing Quality Measures ............... 7
  National Committee for Quality Assurance ................ 7
  Pay for Performance ................................................ 8
  Development of Quality Measures ............................ 9
  Physician Quality Reporting System .......................... 10
  Reporting Options ................................................... 12
  Claims-based Reporting ........................................... 12
  Registry Reporting ................................................... 13
  Electronic Health Record .......................................... 14
  Medicare EHR Incentive Program 2015 ...................... 14
  Stage 1 ..................................................................... 15
  Stage 2 ..................................................................... 18
  Documentation for Non-Percentage-Based Objectives .... 20
  Electronic Prescribing Incentive Program .................... 21
  Group Practice Reporting Option .............................. 21
  Physician Feedback/Value-based Payment Modifier Program ......................................................... 22
  Qualified Clinical Data Registry Reporting ................ 22
  CMS-Certified Survey Vendor ................................... 22
  Accountable Care Organizations ............................... 23

Chapter 3: Selecting and Reporting Quality Measures ............................................................................. 25
  Reporting Options ................................................... 25
  Group Practice/Accountable Care Organization Reporting Option ......................................................... 31
  Electronic Health Records ......................................... 35

Chapter 4: Individual Measure Specifications ..... 39
  Overview of Quality Measure Specifications ............... 39

Measures Category: Acquired Infections, Other .................. 40
  Measure 76. Prevention of Central Venous Catheter (CVC)-Related Bloodstream Infections ............. 40

Measures Category: Adult and Pediatric Kidney Disease ................................................................. 41
  Measure 81. Adult Kidney Disease: Hemodialysis Adequacy: Solute ................................................. 41
  Measure 82. Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute ........................................... 42
  Measure 121. Adult Kidney Disease: Laboratory Testing (Lipid Profile) .............................................. 42
  Measure 122. Adult Kidney Disease: Blood Pressure Management ...................................................... 43

  Measure 327. Pediatric Kidney Disease: Adequacy of Volume Management ........................................ 44
  Measure 328. Pediatric Kidney Disease: ESRD Patients Receiving Dialysis: Hemoglobin Level < 10 g/dL ................................................................. 44
  Measure 329. Adult Kidney Disease: Catheter Use at Initiation of Hemodialysis .................................. 45
  Measure 330. Adult Kidney Disease: Catheter Use for Greater Than or Equal to 90 Days .................. 45

Measures Category: Adult Primary Rhegmatogenous Retinal Detachment Surgery ............................. 47
  Measure 384. Adult Primary Rhegmatogenous Retinal Detachment Repair Success Rate .................. 47
  Measure 385. Adult Primary Rhegmatogenous Retinal Detachment Surgery Success Rate ............. 47

Measures Category: Age-Related Macular Degeneration ............................................................................ 49
  Measure 14. Age-Related Macular Degeneration (AMD): Dilated Macular Examination ................. 49
  Measure 140. Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement ................................................................. 50

Measures Category: Aneurysm .......................................................... 51
  Measure 258. Rate of Open Repair of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) ................................................................. 51
  Measure 259. Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2) ................................................................. 52
  Measure 347. Rate of Endovascular Aneurysm Repair (EVAR) of Small or Moderate Non-Ruptured Abdominal Aortic Aneurysms (AAA) Who Die While in Hospital ................................................................. 52

Measures Category: Arthritis ......................................................... 53
  Measure 109. Osteoarthritis (OA): Function and Pain Assessment ....................................................... 53
  Measure 178. Rheumatoid Arthritis (RA): Functional Status Assessment ........................................... 53

Measures Category: Asthma/URI/Pharyngitis Measures ........................................................................... 55
  Measure 53. Asthma: Pharmacologic Therapy for Persistent Asthma — Ambulatory Care Setting ................................................................. 55
Measure 65. Appropriate Treatment for Children with Upper Respiratory Infection (URI) .......................... 56
Measure 66. Appropriate Testing for Children with Pharyngitis ......................................................... 56
Measure 116. Avoidance of Antibiotic Treatment of/in Adults with Acute Bronchitis: Avoidance of Inappropriate Use ................................................................. 57
Measure 398. Optimal Asthma Control ........................................... 58

**Measures Category: Atrial Fibrillation and Flutter .......................... 60**

Measure 326. Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy ................................. 60
Measure 392. HRS-12: Cardiac Tamponade and/or Pericardiocentesis Following Atrial Fibrillation Ablation .......................................................... 61

**Measures Category: Bypass Graft .......................................... 62**

Measure 43. Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery .................................. 62
Measure 44. Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery .................................................. 63
Measure 164. Coronary Artery Bypass Graft (CABG): Prolonged Intubation ............................................. 63
Measure 165. Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate ...................... 64
Measure 166. Coronary Artery Bypass Graft (CABG): Stroke .................................................................. 64
Measure 167. Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure ................................. 65
Measure 168. Coronary Artery Bypass Graft (CABG): Surgical Re-exploration ........................................ 65
Measure 257. Statin Therapy at Discharge after Lower Extremity Bypass (LEB) ........................................... 66

**Measures Category: Carotid Artery Procedures .......................... 67**

Measure 344. Rate of Carotid Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Postoperative Day #2) ............................................. 67
Measure 345. Rate of Postoperative Stroke or Death in Asymptomatic Patients Undergoing Carotid Artery Stenting (CAS) ........................................... 67

**Measures Category: Cataracts ................................................. 69**

Measure 191. Cataracts: 20/40 or Better Visual Acuity Within 90 Days Following Cataract Surgery ............. 69
Measure 192. Cataracts: Complications Within 30 days Following Cataract Surgery Requiring Additional Surgical Procedures ........................................... 71
Measure 303. Cataracts: Improvement in the Patient’s Visual Function within 90 Days Following Cataract Surgery ........................................................................... 71
Measure 304. Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery .......................... 73
Measure 388. Cataract Surgery with Intra-Operative Complications (Unplanned Rupture of Posterior Capsule Requiring Unplanned Vitrectomy) .............. 74
Measure 389. Cataract Surgery: Difference Between Planned and Final Refraction ................................ 74

**Measures Category: Chronic Obstructive Pulmonary Disease .................................................................. 76**

Measure 51. Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation .............................. 76
Measure 52. Chronic Obstructive Pulmonary Disease (COPD): Inhaled Bronchodilator Therapy ............ 76

**Measures Category: Coronary Artery Disease ................................ 78**

Measure 6. Coronary Artery Disease (CAD): Antiplatelet Therapy ......................................................... 78
Measure 7. Coronary Artery Disease (CAD): Beta-blocker Therapy—Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) ........................................ 79
Measure 118. Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy—Diabetes or Left Ventricular Systolic Dysfunction (LVEF < 40%) ........................................ 80
Measure 242. Coronary Artery Disease (CAD): Symptom Management .............................................. 81

**Measures Category: Depression/Major Depressive Disorder ................................................................ 83**

Measure 134. Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan .............................................................. 83
Measure 325. Adult Major Depressive Disorder (MDD): Coordination of Care of Patients with Specific Comorbid Conditions ...................................... 84

**Measures Category: Diabetes ................................................ 85**

Measure 1. Diabetes: Hemoglobin A1c Poor Control .......... 85
Measure 117. Diabetes: Eye Exam ........................................ 85
Measure 119. Diabetes: Medical Attention for Nephropathy ................................................................ 86
Measure 126. Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy—Neurological Evaluation ........................................................ 87
Measure 127. Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention—Evaluation of Footwear ................. 88
Measure 163. Diabetes: Foot Exam ........................................ 88

**Measures Category: Diabetic Retinopathy ................................ 90**

Measure 19. Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care ............................................................. 90

**Measures Category: Elder Care ............................................... 91**

Measure 47. Care Plan .......................................................... 91
Measure 181. Elder Maltreatment Screen and Follow-up Plan .......................................................... 91
Measure 386. Amyotrophic Lateral Sclerosis (ALS) Patient Care Preferences ........................................ 92

**Measures Category: Emergency Medicine ................................ 94**

Measures Category: Endarterectomy .......................... 95
Measure 260. Rate of Carotid Endarterectomy (CEA) for
Asymptomatic Patients, without Major
Complications (Discharged to Home by
Post-Operative Day #2) ........................................ 95

Measures Category: Endoscopy & Polyp
Surveillance ........................................................... 96
Measure 185. Colonoscopy Interval for Patients
with a History of Adenomatous Polyps—
Avoidance of Inappropriate Use ........................ 96

Measures Category: Epilepsy ....................................... 97
Measure 268. Epilepsy: Counseling for Women of
Childbearing Potential with Epilepsy .............. 97

Measures Category: Fall ................................................. 98
Measure 154. Falls: Risk Assessment .................... 98
Measure 155. Falls: Plan of Care .......................... 99

Measures Category: Functional Deficits .............. 100
Measure 217. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Knee Impairments ................................. 100
Measure 218. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Hip Impairments ................................. 101
Measure 219. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Lower Leg, Foot or Ankle Impairments .... 103
Measure 220. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Lumbar Spine Impairments .................. 104
Measure 221. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Shoulder Impairments ..................... 106
Measure 222. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Elbow, Hand or Wrist Impairments ......... 107
Measure 223. Functional Deficit: Change in
Risk-Adjusted Functional Status for Patients
with Neck, Cranium, Mandible, Thoracic Spine,
Ribs, or Other General Orthopedic
Impairments ................................................... 108

Measures Category: Heart Failure ......................... 111
Measure 5. Heart Failure (HF): Angiotensin-Converting
Enzyme (ACE) Inhibitor or Angiotensin
Receptor Blocker (ARB) Therapy for Left
 Ventricular Systolic Dysfunction (LVSD) ....... 111
Measure 8. Heart Failure (HF): Beta-Blocker
Therapy for Left Ventricular Systolic
Dysfunction (LVSD) ......................................... 112

Measures Category: Hematology and Oncology
Measures .......................................................... 114
Measure 67. Hematology: Myelodysplastic Syndrome
(MDS) and Acute Leukemias: Baseline
Cytogenetic Testing Performed on Bone
Marrow .......................................................... 115
Measure 68. Hematology: Myelodysplastic Syndrome
(MDS): Documentation of Iron Stores in
Patients Receiving Erythropoietin Therapy .... 115
Measure 69. Hematology: Multiple Myeloma: T
  treatment With Bisphosphonates ............ 116
Measure 70. Hematology: Chronic Lymphocytic
Leukemia (CLL): Baseline Flow Cytometry ..... 116
Measure 71. Breast Cancer: Hormonal Therapy for
Stage IC-IIIC Estrogen Receptor/Progesterone
Receptor (ER/PR) Positive Breast Cancer .... 117
Measure 72. Colon Cancer: Chemotherapy for
AJCC Stage III Colon Cancer Patients ............ 118
Measure 99. Breast Cancer Resection Pathology
Reporting: Pt Category (Primary Tumor) and
pN Category (Regional Lymph Nodes) with
Histologic Grade .............................................. 119
Measure 100. Colorectal Cancer Resection
Pathology: pT Category (Primary Tumor)
and pN Category (Regional Lymph Nodes)
with Histologic Grade ................................. 119
Measure 102. Prostate Cancer: Avoidance of
Overuse of Bone Scan for Staging Low-Risk
Prostate Cancer Patients ............................. 120
Measure 104. Prostate Cancer: Adjuvant
Hormonal Therapy for High-Risk Prostate
Cancer Patients ............................................. 120
Measure 143. Oncology: Medical and Radiation—
  Pain Intensity Quantified ......................... 121
Measure 144. Oncology: Medical and Radiation—
  Plan of Care for Pain ............................... 121
Measure 156. Oncology: Radiation Dose Limits to
Normal Tissues .................................................. 122
Measure 194. Oncology: Cancer Stage
Documented .................................................. 122
Measure 263. Preoperative Diagnosis of Breast
Cancer .......................................................... 123
Measure 264. Sentinel Lymph Node Biopsy for
Invasive Breast Cancer ............................... 124
Measure 395. Lung Cancer Reporting
(Biopsy/Cytology Specimens) ...................... 124
Measure 396. Lung Cancer Reporting
(Resection Specimens) ............................... 125

Measures Category: Hepatitis C ............................. 126
Measure 387. Annual Hepatitis C Virus (HCV)
Screening for Patient who are Active Injection
Drug Users ..................................................... 126
Measure 390. Discussion and Shared Decision
Making Surrounding Treatment Options .......... 126
Measure 400. Hepatitis C: One-Time Screening for
Hepatitis C Virus (HCV) for Patients at Risk ... 127
Measure 401. Screening for Hepatocellular
Carcinoma (HCC) in Patients with Hepatitis
Cirrhosis ......................................................... 128

Measures Category: Human Immunodeficiency
Virus/Acquired Immune Deficiency ................. 129
Measure 205. HIV/AIDS: Sexually Transmitted Disease
Screening for Chlamydia, Gonorrhea, and
Syphilis ......................................................... 129

Measures Category: Hypertension ......................... 130
Measure 236. Controlling High Blood Pressure ...... 130
### Measures Category: Ischemic Vascular Disease (IVD)

- Measure 204. Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic ........................................ 131
- Measure 349. Optimal Vascular Care Composite .......... 131

### Measures Category: Medication Reconciliation

- Measure 46. Medication Reconciliation ............................. 133
- Measure 130. Documentation of Current Medications in the Medical Record ................................................. 133

### Measures Category: Melanoma

- Measure 137. Melanoma: Continuity of Care—Recall System ......................................................... 135
- Measure 138. Melanoma: Coordination of Care .......... 135
- Measure 397. Melanoma Reporting ............................... 137

### Measures Category: Mental Health

- Measure 391. Follow-up After Hospitalization for Mental Illness (FUH) ............................................. 138

### Measures Category: Ocular Disorders Other Than Cataract

- Measure 12. Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation ..................................... 139
- Measure 141. Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care ............................................. 139

### Measures Category: Osteoporosis

- Measure 24. Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older ........................................ 141
- Measure 39. Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older ...................... 142
- Measure 40. Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older ........................................ 143
- Measure 41. Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older .............. 144

### Measures Category: Otitis

- Measure 91. Acute Otitis Externa (AOE): Topical Therapy ........................................................................ 145
- Measure 93. Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy—Avoidance of Inappropriate Use ...................................................... 145

### Measures Category: Otological Evaluation

- Measure 261. Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness .......... 147

### Measures Category: Pacemaker and Implantable Cardioverter-Defibrillator

- Measure 348. HRS-3: Implantable Cardioverter-Defibrillator (ICD) Complications Rate ....................... 148

- Measure 393. Infection within 180 Days of Cardiac Implantable Electronic Device (CIED) Implantation, Replacement, or Revision .......... 149

### Measures Category: Pain Management

- Measure 311. Pain Assessment and Follow-up ............. 150
- Measure 342. Pain Brought Under Control within 48 Hours ........................................................................ 151

### Measures Category: Pathology and Laboratory Reports

- Measure 249. Barrett’s Esophagus ................................ 152
- Measure 250. Radical Prostatectomy Pathology Reporting ................................................................. 152
- Measure 265. Biopsy Follow-Up .................................... 154

### Measures Category: Perioperative Treatments

- Measure 21. Perioperative Care: Selection of Prophylactic Antibiotic—First OR Second Generation Cephalosporin ........................................ 155
- Measure 22. Perioperative Care: Discontinuation of Prophylactic Parenteral Antibiotics (Non-Cardiac Procedures) ........................................ 156
- Measure 23. Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) .................................. 157
- Measure 193. Perioperative Temperature Management ............................................................................. 157
- Measure 399. Post-Procedural Optimal Medical Therapy Composite (Percutaneous Coronary Intervention) ......................................................... 158

### Measures Category: Pregnancy

- Measure 254. Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain ............................................. 160
- Measure 255. Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure ........................................ 161
- Measure 335. Maternity Care: Elective Delivery or Early Induction Without Medical Indication at ≥ 37 and < 39 Weeks ................................ 161
- Measure 336. Maternity Care: Post-Partum Follow-up and Care Coordination .......................................... 162

### Measures Category: Preventive Care and Screening

- Measure 110. Preventive Care and Screening: Influenza Immunization ................................................. 163
- Measure 111. Pneumonia Vaccination Status for Older Adults ........................................................................ 164
- Measure 112. Breast Cancer Screening .................................... 164
- Measure 113. Colorectal Cancer Screening ..................... 165
- Measure 128. Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan .................................................. 166
- Measure 173. Preventive Care and Screening: Unhealthy Alcohol Use—Screening .................................. 167
Measures Category: Radiology/Nuclear Medicine Services .......................................................... 173

Measure 145. Radiology: Exposure Time Reported for Procedures Using Fluoroscopy .... 173
Measure 146. Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Screening Mammograms .................................................. 174
Measure 147. Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy .............................. 174
Measure 225. Radiology: Reminder System for Screening Mammograms ............................. 175
Measure 262. Image Confirmation of Successful Excision of Image-Localized Breast Lesion .... 175
Measure 322. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Preoperative Evaluation in Low Risk Surgery Patients .............. 176
Measure 323. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Routine Testing After Percutaneous Coronary Intervention (PCI) ...... 176
Measure 324. Cardiac Stress Imaging Not Meeting Appropriate Use Criteria: Testing in Asymptomatic, Low-Risk Patients ........................................ 177

Measures Category: Rehabilitation ................................................. 178

Measure 243. Cardiac Rehabilitation Patient Referral from an Outpatient Setting ........ 178

Measures Category: Sinusitis .................................................. 180

Measure 312. Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use) .................................................. 181
Measure 333. Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse) .......................................................... 181
Measure 334. Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse) .................................................. 182

Measures Category: Stroke .................................................. 183

Measure 32. Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy .......... 183
Measure 33. Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge ............................. 184
Measure 187. Stroke and Stroke Rehabilitation: Thrombolytic Therapy .............................. 184
Measure 195. Radiology: Stenosis Measurement in Carotid Imaging Reports ................. 185

Measures Category: Urinary Incontinence Measures ................................................. 186

Measure 48. Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older ................. 186
Measure 50. Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older .................................................. 186

Chapter 5: Measures Groups ............................................... 189

Measures Groups Specifications ............................................. 191

Acute Otitis Externa (AOE) Measures Group ............................................. 191
Asthma Measures Group ............................................................................. 192
Cataracts Measures Group ........................................................................ 192
Chronic Kidney Disease (CKD) Measures Group ................................ 193
Chronic Obstructive Pulmonary Disease (COPD) Measures Group ................. 194
Coronary Artery Bypass Graft (CABG) Measures Group ........................ 194
Coronary Artery Disease (CAD) Measures Group ...................................... 195
Dementia Measures Group ......................................................................... 196
Diabetes Measures Group ......................................................................... 197
General Surgery Measures Group ............................................................. 198
Heart Failure (HF) Measures Group .......................................................... 199
Hepatitis C Measures Group ...................................................................... 199
HIV/AIDS Measures Group ...................................................................... 200
Inflammatory Bowel Disease (IBD) Measures Group .............................. 201
Oncology Measures Group ........................................................................ 201
Optimizing Patient Exposure to Ionizing Radiation Measures Group ............ 202
Parkinson’s Disease Measures Group ..................................................... 203
Preventive Care Measures Group ............................................................. 203
Rheumatoid Arthritis (RA) Measures Group .......................................... 204
Sinusitis Measures Group ......................................................................... 205
Sleep Apnea Measures Group .................................................................... 206
Total Knee Replacement Measures Group .............................................. 206

Chapter 6: Measure Worksheets .............................................. 207

Chapter 7: Condition Worksheets ............................................ 395

COPD Worksheet ........................................................................ 396
Adult Asthma Worksheet .......................................................... 397
CAD Worksheet ........................................................................ 398
Heart Failure Worksheet .......................................................... 399
Preventive Care Worksheet ........................................................ 400
Ischemic Vascular Disease Worksheet ................................................ 402

Glossary .......................................................... 403
## Measures Category: Hematology and Oncology Measures

<table>
<thead>
<tr>
<th>Measure Number</th>
<th>Measure Title</th>
<th>Reporting Options</th>
<th>Reporting Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cyto genetic Testing Performed on Bone Marrow</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>68</td>
<td>Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>69</td>
<td>Hematology: Multiple Myeloma: Treatment With Bisphosphonates</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>70</td>
<td>Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>71</td>
<td>Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer</td>
<td>Claims-Based X, X, X, X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>72</td>
<td>Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients</td>
<td>Claims-Based X, X, X, X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>99</td>
<td>Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade</td>
<td>Claims-Based X</td>
<td>At each pathological examination.</td>
</tr>
<tr>
<td>100</td>
<td>Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade</td>
<td>Claims-Based X</td>
<td>At each pathological examination.</td>
</tr>
<tr>
<td>102</td>
<td>Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients</td>
<td>Claims-Based X</td>
<td>Once per treatment episode.</td>
</tr>
<tr>
<td>104</td>
<td>Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients</td>
<td>Claims-Based X</td>
<td>Once per treatment episode.</td>
</tr>
<tr>
<td>143</td>
<td>Oncology: Medical and Radiation—Pain Intensity Quantified</td>
<td>Claims-Based X, X, X</td>
<td>At each visit.</td>
</tr>
<tr>
<td>144</td>
<td>Oncology: Medical and Radiation—Plan of Care for Pain</td>
<td>Claims-Based X, X</td>
<td>At each visit.</td>
</tr>
<tr>
<td>156</td>
<td>Oncology: Radiation Dose Limits to Normal Tissues</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>194</td>
<td>Oncology: Cancer Stage Documented</td>
<td>Claims-Based X</td>
<td>Once per the reporting period.</td>
</tr>
<tr>
<td>263</td>
<td>Preoperative Diagnosis of Breast Cancer</td>
<td>Claims-Based X</td>
<td>Each time an eligible patient undergoes a breast cancer surgery during the reporting period.</td>
</tr>
<tr>
<td>264</td>
<td>Sentinel Lymph Node biopsy for Invasive Breast Cancer</td>
<td>Claims-Based X</td>
<td>Each time an eligible patient undergoes an SLN procedure during the reporting period.</td>
</tr>
<tr>
<td>395</td>
<td>Lung Cancer Reporting (Biopsy/Cytology Specimens)</td>
<td>Claims-Based X</td>
<td>Each time.</td>
</tr>
<tr>
<td>396</td>
<td>Lung Cancer Reporting (Resection Specimens)</td>
<td>Claims-Based X</td>
<td>Each time.</td>
</tr>
</tbody>
</table>
Measure 67. Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow

**Description:**
This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of MDS or an acute leukemia who had baseline cytogenic testing performed on bone marrow.

**Associated Denominator Codes:**
The ICD-9-CM code indicating acute leukemia not in remission (ICD-9-CM codes 204.00, 204.02, 205.00, 205.02, 206.00, 206.02, 207.00, 207.02, 207.20, 207.22, 208.00, 208.02, 238.72–238.75) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

**Associated Numerator Codes:**
3155F Cytogenetic testing performed on bone marrow at time of diagnosis or prior to initiating treatment (HEM)

**Associated Performance Modifiers:**
1P Performance measure not performed, due to medical reasons
2P Performance measure not performed, due to patient reasons
3P Performance measure not performed, due to system reasons
8P Performance measure not performed, reason not otherwise specified

**Reporting Requirements:**
- There are no allowable performance exclusions for this measure.
- Baseline cytogenetic testing is defined as testing performed at the time of diagnosis or prior to initiating treatment such as transfusion, growth factors, or antineoplastic therapy for that diagnosis.
- If the medical documentation references baseline bone marrow cytogenetic testing at the time of diagnosis or before the initiation of treatment, report 3155F.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to medical reasons that exclude the patient from the denominator, report 3155F with exclusion modifier 1P.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to patient reasons that exclude the patient from the denominator, report 3155F with exclusion modifier 2P.
- If the medical documentation does not reference baseline bone marrow cytogenetic testing at the time of diagnosis or prior to the initiation of therapy due to system reasons that exclude the patient from the denominator, report 3155F with exclusion modifier 3P.
- If there is no documentation of baseline bone marrow cytogenetic testing in the medical documentation at the time of diagnosis or prior to initiating therapy and the reason is not specified, report 3155F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure’s denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 3155F (with modifier 1P, 2P, 3P, or 8P as applicable) does not have to be reported. However, these codes may be reported for registries that utilize claims data.

Measure 68. Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy

**Description:**
This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of MDS who are receiving erythropoietin therapy with documentation of iron stores prior to initiating erythropoietin therapy.

**Associated Denominator Codes:**
The ICD-9-CM code indicating MDS (ICD-9-CM codes 238.72–238.75), the patient encounter code (CPT codes 99201–99205, 99212–99215) and Category II code 4090F indicating the patient is receiving erythropoietin therapy identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

**Associated Numerator Codes:**
3160F Documentation of iron stores prior to initiating erythropoietin therapy (HEM)

**Associated Performance Modifiers:**
3P Performance measure not performed, due to system reasons
8P Performance measure not performed, reason not otherwise specified

**Reporting Requirements:**
- There are no allowable performance exclusions for this measure.
- Documentation of iron stores requires one of two documents contained in the medical record: bone marrow examination including iron stain or serum iron measurement, including ferritin, serum iron, and TIBC.
- Erythropoietin therapy includes epoetin and darbepoetin for purposes of this measure.
- If the medical documentation references iron stores prior to the initiation of erythropoietin therapy, report 3160F.
• If the medical documentation does not reference iron stores prior to the initiation of erythropoietin therapy due to system reasons that exclude the patient from the denominator, report 3160F with exclusion modifier 3P.

• If there is no documentation of iron stores in the medical documentation prior to initiating erythropoietin therapy, and the reason is not specified, report 3160F with modifier 8P.

• This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure’s denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data codes 3160F (with modifier 3P or 8P as applicable), 4090F, and 4095F do not have to be reported. However, these codes may be reported for registries that utilize claims data.

Measure 69. Hematology: Multiple Myeloma: Treatment With Bisphosphonates

Description:
This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of multiple myeloma, NOT in remission, who were prescribed or received bisphosphonate therapy within the 12-month reporting period.

Associated Denominator Codes:
The ICD-9-CM code indicating multiple myeloma (ICD-9-CM codes 203.00, 203.02) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:
4100F Bisphosphonate therapy, intravenous, ordered or received (HEM)

Associated Performance Modifiers:
1P Performance measure not performed, due to medical reasons
2P Performance measure not performed, due to patient reasons
8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:
• There are no allowable performance exclusions for this measure.
• Prescribed medication includes patients who are currently receiving medications that follow the treatment plan recommended at an encounter during the reporting period, even if the prescription for that medication was ordered prior to the encounter.
• Bisphosphate therapy includes pamidronate and zoledronate for purposes of this measure.

• When intravenous bisphosphate therapy is prescribed or received, report 4100F.
• When the bisphosphate therapy is NOT prescribed or is NOT received by the patient for medical reasons, report 4100F with exclusion modifier 1P.
• When the bisphosphate therapy is NOT prescribed or is NOT received by the patient for patient reasons, report 4100F with exclusion modifier 2P.
• When the therapy is NOT prescribed and medical record documentation does not indicate a reason, report 4100F with modifier 8P.

• This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure’s denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 4100F (with modifier 1P, 2P, or 8P as applicable) does not have to be reported. However, it may be reported for registries that utilize claims data.

Measure 70. Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry

Description:
This quality measure identifies the percentage of patients aged 18 years or older with a diagnosis of CLL who had baseline flow cytometry studies performed.

Associated Denominator Codes:
The ICD-9-CM code indicating a diagnosis with CLL not in remission (ICD-9-CM codes 204.10, 204.12) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:
3170F Flow cytometry studies performed at time of diagnosis or prior to initiating treatment (HEM)

Associated Performance Modifiers:
1P Performance Measure not performed, due to medical reasons
2P Performance measure not performed, due to patient reasons
3P Performance measure not performed, due to system reasons
8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:
• There are no allowable performance exclusions for this measure.
- CMS defines baseline flow cytometry studies to be testing that is performed at time of diagnosis or prior to initiating treatment for that diagnosis. Treatment may include antineoplastic therapy.
- If the patient has baseline flow cytometry studies performed, report 3170F.
- If the patient was not prescribed or did not receive baseline flow cytometry studies performed because one of the exclusion criteria was documented, report 3170F with the appropriate exclusion modifier:
  - 1P Performance measure not performed, due to medical reasons
  - 2P Performance measure not performed, due to patient reasons
  - 3P Performance measure not performed, due to system reasons
- If the patient was not prescribed or did not undergo baseline flow cytometry studies and the reason is not specified, report 3170F with modifier 8P.
- This measure is reported via registry only. Patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure’s denominator. The numerator options as described above are used to report the numerator of the measure. Quality-data code 3170F (with modifier 1P, 2P, 3P, or 8P as applicable) does not have to be reported. However, it may be reported for registries that utilize claims data.

**Measure 71. Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer**

**Description:**
This quality measure identifies the percentage of female patients aged 18 years or older with a diagnosis of stage IC-IIIC, ER/PR positive breast cancer prescribed hormonal therapy, such as tamoxifen or aromatase inhibitor (AI), during the 12-month reporting period.

**Associated Denominator Codes:**
The ICD-9-CM code indicating a diagnosis of breast cancer (ICD-9-CM codes 174.0-174.6, 174.8, 174.9) and the patient encounter code (CPT codes 99201–99205, 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10–CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

**Associated Numerator Codes:**
- 3315F Estrogen receptor (ER) and progesterone receptor (PR) Positive breast cancer (ONC)
- 3316F Estrogen receptor (ER) and progesterone receptor (PR) Negative breast cancer (ONC)
- 3370F AJCC Breast Cancer Stage 0, documented (ONC)
- 3372F AJCC Breast Cancer Stage I: T1 mic, T1a or T1b (tumor size ≤ 1cm), documented (ONC)
- 3374F AJCC Breast Cancer Stage I: T1c (tumor size > 1cm to 2cm), documented (ONC)
- 3376F AJCC Breast Cancer Stage II, documented (ONC)
- 3378F AJCC Breast Cancer Stage III, documented (ONC)
- 3380F AJCC Breast Cancer Stage IV, documented (ONC)
- 4179F Tamoxifen or aromatase inhibitor (AI) prescribed (ONC)

**Associated Performance Modifiers:**
- 1P Performance measure not performed, due to medical reasons
- 2P Performance measure not performed, due to patient reasons
- 3P Performance measure not performed, due to system reasons
- 8P Performance measure not performed, reason not otherwise specified

**Reporting Requirements:**
- There are no allowable performance exclusions for this measure.
- Prescribed is defined by CMS as including the prescription given to the patient for tamoxifen or aromatase inhibitor (AI) at one or more visits in the 12-month reporting period OR according to a current medication list, the patient is already taking one of these drugs.
- If tamoxifen or aromatase inhibitor is prescribed, report the code for tamoxifen or aromatase inhibitor (AI) prescribed (4179F), a code indicating the positive receptor (3315F), and the appropriate breast cancer staging code from below:
  - 3374F AJCC Breast Cancer Stage I: T1c (tumor size > 1cm to 2cm), documented
  - 3376F AJCC Breast Cancer Stage II, documented
  - 3378F AJCC Breast Cancer Stage III, documented
- If the patient was not prescribed or did not receive tamoxifen or aromatase inhibitor at the time of the visit for medical, patient, or system reasons, report 4179F with the appropriate exclusion modifier:
  - 1P Performance measure not performed, due to medical reasons
  - 2P Performance measure not performed, due to patient reasons
  - 3P Performance measure not performed, due to system reasons
- AND the appropriate staging code from the list above, as well as the receptor code (3315F).
- If the patient is not eligible for this measure because the patient is estrogen (ER) and progesterone receptor (PR) negative, report 3316F.
- If the patient is not eligible for this measure because the stage of cancer is not stage 1c through 111c breast cancer, report one of the following:
  - 3370F AJCC Breast Cancer Stage 0, documented
  - 3372F AJCC Breast Cancer Stage I: T1 mic, T1a or T1b (tumor size ≤ 1cm), documented
  - 3380F AJCC Breast Cancer Stage IV, documented
Measure 72. Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients

Description:
This quality measure identifies the percentage of patients, aged 18 to 80 years, with a diagnosis of AJCC stage III colon cancer who were referred, prescribed, or who previously received adjuvant chemotherapy during the reporting period.

Associated Denominator Codes:
The ICD-9-CM code indicating a diagnosis of colon cancer (ICD-9-CM codes 153.0-153.4, 153.6–153.9) and the patient encounter code (CPT codes 99201–99205 and 99212–99215) identify eligible patients for this measure.

For the most current list of associated numerators and denominators, including the ICD-10-CM denominators, see the Quality Data Numerator and Denominator Resource at www.OptumCoding.com/Product/Updates/PQRS15.

Associated Numerator Codes:
- 3382F AJCC Colon Cancer Stage 0, documented (ONC)
- 3384F AJCC Colon Cancer Stage I, documented (ONC)
- 3386F AJCC Colon Cancer Stage II, documented (ONC)
- 3388F AJCC Colon Cancer Stage III, documented (ONC)
- 3390F AJCC Colon Cancer Stage IV, documented (ONC)
- G8927 Adjuvant chemotherapy referred, prescribed or previously received for AJCC Stage III colon cancer
- G8928 Adjuvant chemotherapy not prescribed or previously received, reason given
- G8929 Adjuvant chemotherapy not prescribed or previously received, reason not given

Associated Performance Modifiers:
- 8P Performance measure not performed, reason not otherwise specified

Reporting Requirements:
- There are no allowable performance exclusions for this measure.
- CMS defines adjuvant chemotherapy using current NCCN guidelines. The following therapies are recommended:
  - 5-FU/LV/oxaliplatin (mFOLFOX6) as the standard of care (category 1)
  - bolus 5-FU/LV/oxaliplatin (FLOX, category 1)
  - capecitabine/oxaliplatin (CapeOx, category 1)
  - single agent capecitabine (category 2A) or 5-FU/LV (category 2A) in patients felt to be inappropriate for oxaliplatin therapy
- The definition of prescribed includes a prescription ordered for the patient for adjuvant chemotherapy at one or more visits in the 12-month period or patient already receiving adjuvant chemotherapy as documented in the current medication list.
- If the patient was referred for, prescribed, or previously received neoadjuvant or adjuvant chemotherapy, report 3388F and G8927.
- If the patient was not referred, prescribed, or not receiving chemotherapy for a documented reason, report 3388F and G8928.
- If the patient was not referred for, prescribed, or receiving chemotherapy and the reason is not given, report 3388F and G8929.
- If the patient is not eligible for this measure because the stage of cancer is not documented, report 3382F with modifier 8P.
- If the patient is not eligible for this measure because the patient is not stage III colon cancer, report one of the following:
  - 3382F AJCC Colon Cancer Stage 0, documented
  - 3384F AJCC Colon Cancer Stage I, documented
  - 3386F AJCC Colon Cancer Stage II, documented
  - 3390F AJCC Colon Cancer Stage IV, documented
- This measure is included in the Oncology Measures Group. See the Group Measures section for more information regarding the reporting of this measures group.
- This measure is reportable only through a registry and the EHR reporting options. When reporting via a registry, the patient demographics, as well as the ICD-9-CM and CPT codes, are used to identify patients who are included in the measure's denominator. The numerator options as described above are used to report the numerator of the measure. The quality-data codes described above do not have to be reported. However, these codes may be reported for registries that utilize claims data.